44.200.169.3
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-

Diabetic Macular Edema

FDA approves Beovu for diabetic macular edema

The US Food and Drug Administration (FDA) has approved Beovu (brolucizumab; Novartis) 6 mg for the treatment of diabetic macular edema (DME), according to a press release. This is the second FDA-approved indication for brolucizumab, which was approved for the treatment of wet age-related macular degeneration in 2019. “The FDA...

Read More
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-